Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $6.1 million.

  • BridgeBio Pharma's Depreciation & Amortization (CF) fell 9.10% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 14.73%. This contributed to the annual value of $6.1 million for FY2024, which is 6.45% down from last year.
  • BridgeBio Pharma's Depreciation & Amortization (CF) amounted to $6.1 million in FY2024, which was down 6.45% from $6.5 million recorded in FY2023.
  • BridgeBio Pharma's Depreciation & Amortization (CF)'s 5-year high stood at $6.8 million during FY2022, with a 5-year trough of $1.5 million in FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $6.5 million (2023), whereas its average is $6.4 million.
  • Per our database at Business Quant, BridgeBio Pharma's Depreciation & Amortization (CF) surged by 301.30% in 2021 and then declined by 6.45% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Depreciation & Amortization (CF) (Yearly) stood at $1.5 million in 2020, then surged by 301.30% to $5.8 million in 2021, then rose by 15.88% to $6.8 million in 2022, then declined by 4.09% to $6.5 million in 2023, then fell by 6.45% to $6.1 million in 2024.